Atea Q1 net loss $35.5M ($0.43/share); cash $620.5M; progresses bemnifosbuvir trials

Atea Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.43

Net loss of $35.5M ($0.43 diluted EPS) vs $42.1M ($0.51) in Q1 2022; no revenue.
Cash, cash equivalents & marketable securities $620.5M at March 31, 2023 vs $646.7M at Dec 31, 2022.
R&D expense $29.0M, G&A $12.6M; both roughly flat YoY; interest income rose to $6.3M.
FDA granted Fast Track designation for bemnifosbuvir in COVID-19; Phase 3 SUNRISE-3 enrolling.
Phase 2 HCV combination (bemnifosbuvir + ruzasvir) dosing expected 2Q23; initial data 4Q23; dengue program deprioritized.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atea Pharmaceuticals, Inc. reported financial results for the three months ended March 31, 2023.

Period: the three months ended March 31, 2023
Result: reported results

Exact text from the filing

On May 8, 2023, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the three months ended March 31, 2023 and other matters described in the press release.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-138257

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.